IMARC Group's report titled "Oncolytic Virus Therapies Market Report by Virus Type (Genetically Engineered Oncolytic Viruses, Oncolytic Wild-Type Viruses), Application (Solid Tumors, Melanoma), End Use (Hospitals, Specialty Clinics, Cancer Research Institute), and Region 2024-2032". The global oncolytic virus therapies market size reached US$ 162.7 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 709.0 Million by 2032, exhibiting a growth rate (CAGR) of 17.23% during 2024-2032.

For an in-depth analysis, you can refer sample copy of the report: https://www.imarcgroup.com/oncolytic-virus-therapies-market/requestsample

Factors Affecting the Growth of the Oncolytic Virus Therapies Industry:

Patient-Centric Treatment Approaches:
The growing shift towards patient-centric treatment approaches in oncology, where treatments are tailored to individual patient characteristics, including the genetic profile of their tumors, is positively influencing the market. Oncolytic viruses offer the potential for customization to target specific cancer cells while sparing normal cells, thereby reducing side effects and improving patient outcomes. This personalized strategy not only improves the efficacy of cancer treatments but also aligns with patient preferences for therapies that are tailored to their unique condition, thereby increasing patient acceptance and demand for such innovative treatments. The focus on patient-centric strategies is encouraging the development of more sophisticated oncolytic viral therapies, catering to the rising demand for personalized and precise cancer treatments.
Technological Advancements in Therapy Development:
The continuous advancements in genetic engineering and virology are enabling the development of more sophisticated and targeted oncolytic viruses, enhancing their safety, efficacy, and delivery mechanisms. Moreover, improved genetic engineering techniques allow for the precise modification of viruses to target cancer cells selectively, increasing therapeutic potential while minimizing side effects. Additionally, advancements in bioinformatics and molecular biology are facilitating the design of viruses that can elicit a stronger immune response against tumors. The integration of these technologies accelerates the pace of clinical trials, supports the customization of therapies for individual patients, and broadens the scope of treatable cancers.
Increased Investment and Collaborative Efforts:
The rising financial investments and collaborative efforts between biotechnology companies, pharmaceutical giants, and research institutions, are contributing to the market growth. The potential of oncolytic virus therapies to offer less toxic and more targeted alternatives to traditional cancer treatments is attracting notable funding from both the public and private sectors. This influx of capital is essential for conducting extensive research, advancing clinical trials, and scaling up production. Furthermore, strategic partnerships and collaborations are pivotal in combining expertise, technology, and resources, accelerating the development and commercialization of innovative therapies. These alliances are instrumental in overcoming the scientific, regulatory, and economic challenges inherent in bringing new treatments.
Leading Companies Operating in the Global Oncolytic Virus Therapies Industry:
Amgen Inc.
Dnatrix Inc.
Genelux Corporation
Lokon Pharma AB
Replimune Group Inc.
Rigvir Ltd.
Sorrento Therapeutics
Takara Bio Inc. (Takara Holdings Inc.)
Targovax
TILT Biotherapeutics Ltd
Transgene SA
Vyriad
Oncolytic Virus Therapies Market Report Segmentation:
By Virus Type:
Genetically Engineered Oncolytic Viruses
Herpes Simplex Virus
Adenovirus
Vaccinia Virus
Oncolytic Wild-Type Viruses
Reovirus
Newcastle Disease Virus
Vesicular Stomatitis Virus
Based on the virus type, the market has been bifurcated into genetically engineered oncolytic viruses (herpes simplex virus, adenovirus, and vaccinia virus) and oncolytic wild-type viruses (reovirus, newcastle disease virus, and vesicular stomatitis virus).
By Application:
Solid Tumors
Breast Cancer
Prostate Cancer
Lung Cancer
Glioblastoma
Melanoma
Hematological Malignancies
Lymphoma
Leukemia
Myeloma
On the basis of the application, the market has been classified into solid tumors (breast cancer, prostate cancer, lung cancer, and glioblastoma) and melanoma (hematological malignancies, lymphoma, leukemia, and myeloma).
By End Use:
Hospitals
Specialty Clinics
Cancer Research Institute
Based on the end use, the market has been segregated into hospitals, specialty clinics, and cancer research institute.
Regional Insights:
North America (United States, Canada)
Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
Latin America (Brazil, Mexico, Others)
Middle East and Africa
North America dominates the market owing to the existence of advanced healthcare infrastructure, rising investments in research operations for cancer therapies, and the presence of leading biotech and pharmaceutical companies engaged in oncolytic virus therapy development.
Global Oncolytic Virus Therapies Market Trends:
The growing strategic combination of oncolytic viruses with other cancer therapies, including immune checkpoint inhibitors, chemotherapy, and radiation therapy, is enhancing the overall therapeutic efficacy by synergistically improving the response of the immune system to cancer. This combinational approach not only helps to improve patient outcomes but also expands the therapeutic potential of oncolytic viruses across a wider range of cancer types.
Additionally, the rising employment of cutting-edge immunotherapy techniques to engineer oncolytic viruses that can more effectively enable the immune system against cancer cells is offering a dual attack mechanism combining direct oncolysis with immune-mediated tumor destruction.
Note: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARCs information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.
Contact US:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163

Items